SCHEMBL968657

SCHEMBL968657

CC(C)=CCc1c(O)c2c(c3c1CCC(C)(C)O3)C1CCC2C1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE9A O76083 1/20 0.41
CYP19A1 P11511 3/20 0.40
NUDT1 P36639 1/20 0.39
PTGS2 P35354 1/20 0.37
CCR5 P51681 1/20 0.36
CTSL P07711 1/20 0.34
MAOA P21397 3/20 0.33
MAOB P27338 3/20 0.33
OSBP P22059 1/20 0.32
ABCG2 Q9UNQ0 1/20 0.32
MEN1 O00255 1/20 0.32
POLB P06746 1/20 0.32
MAPT P10636 1/20 0.32
XBP1 P17861 1/20 0.32
KMT2A Q03164 1/20 0.32
PTPN1 P18031 1/20 0.32
PTGES O14684 1/20 0.31
ALOX5 P09917 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL967680 0.95 CYP19A1 (0.41) PDE9ACYP19A1NUDT1PTGS2CCR5
SCHEMBL969062 0.84 CCR5 (0.40) CCR5
SCHEMBL969716 0.83 NUDT1 (0.38) PDE9ACYP19A1NUDT1PTGS2CCR5
SCHEMBL970035 0.83 CYP19A1 (0.41) PDE9ACYP19A1NUDT1PTGS2CCR5
SCHEMBL968424 0.82 ALOX5 (0.45) CTSLPTGESALOX5
SCHEMBL969673 0.79 CCR5 (0.36) CCR5MEN1MAPTKMT2A
SCHEMBL1285627 0.78 CYP19A1 (0.44) PDE9ACYP19A1NUDT1PTGS2CCR5
SCHEMBL968168 0.78 ALOX5 (0.46) CTSLALOX5
SCHEMBL969447 0.77 CCR5 (0.35) CCR5
SCHEMBL6243212 0.77 CTSL (0.37) PDE9ACYP19A1NUDT1PTGS2CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7875607-B2 Neurodegenerative disorders; antiinflammatory agents; antiischemic agents; neuropathic pain; antiepileptic agents; Parkinson's disease; Alzheimer's disease; antidiabetic agents; 3-(6-Hydroxy-2-methyl-3,4,7,8,9,10-hexahydro-7,10-methano-2H -benzo[h]chromen-2-yl)-propionic acid methyl ester AMPERE LIFE SCIENCES, INC. (US) 2011-01-25 US disclosed
US-20090170814-A1 7,8-BICYCLOAKYL-CHROMAN DERIVATIVES EDISON PHARMACEUTICALS, INC. (US) 2009-07-02 US disclosed
US-7470798-B2 Neurodegenerative disorders; antiinflammatory agents; strokes; antiischemic agents; neuropathic pain; brain disorders; antiepileptic agents; Parkinson's disease ; amyotropic lateral sclerosis; Alzheimer's disease; antidiabetic agents EDISON PHARMACEUTICALS, INC. (US) 2008-12-30 US disclosed
US-20050065149-A1 Neurodegenerative disorders; antiinflammatory agents; strokes; antiischemic agents; neuropathic pain; brain disorders; antiepileptic agents; Parkinson's disease ; amyotropic lateral sclerosis; Alzheimer's disease; antidiabetic agents PTC THERAPEUTICS, INC. 2005-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065149-A1 Neurodegenerative disorders; antiinflammatory agents; strokes; antiischemic agents; neuropathic pain; brain disorders; antiepileptic agents; Parkinson's disease ; amyotropic lateral sclerosis; Alzheimer's disease; antidiabetic agents NLN, ACAA2, CS PDE9A 3248/4885CYP19A1 2232/4885NUDT1 1930/4885
US-20090170814-A1 7,8-BICYCLOAKYL-CHROMAN DERIVATIVES COQ8A, TFAM, CS PDE9A 766/4885CYP19A1 298/4885NUDT1 1909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.